These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6112551)

  • 1. Observations in hypothyroid patients following change in thyroxine tablet formulation.
    Matthews HL; Brelsford J; Baker SE; Ashwell K; Hopton MR; Harrop JS
    Lancet; 1981 May; 1(8231):1211. PubMed ID: 6112551
    [No Abstract]   [Full Text] [Related]  

  • 2. Tablet and oral liquid L-thyroxine formulation in the treatment of naïve hypothyroid patients with Helicobacter pylori infection.
    Ribichini D; Fiorini G; Repaci A; Castelli V; Gatta L; Vaira D; Pasquali R
    Endocrine; 2017 Sep; 57(3):394-401. PubMed ID: 27848196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series.
    Fallahi P; Ferrari SM; Ruffilli I; Antonelli A
    BMC Gastroenterol; 2016 Feb; 16():22. PubMed ID: 26965518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study.
    Fallahi P; Ferrari SM; Antonelli A
    Endocrine; 2016 Jun; 52(3):597-601. PubMed ID: 26721663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potency of brand name and generic levothyroxine.
    Stoffer SS; Szpunar WE
    JAMA; 1980 Oct; 244(15):1704-5. PubMed ID: 7411829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shift from Levothyroxine Tablets to Liquid Formulation at Breakfast Improves Quality of Life of Hypothyroid Patients.
    Guglielmi R; Grimaldi F; Negro R; Frasoldati A; Misischi I; Graziano F; Cipri C; Guastamacchia E; Triggiani V; Papini E
    Endocr Metab Immune Disord Drug Targets; 2018; 18(3):235-240. PubMed ID: 29376496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Study of Patients Switched from Tablet Formulations to a Gel Cap Formulation of Levothyroxine: Results of the CONTROL Switch Study.
    Ernst FR; Sandulli W; Elmor R; Welstead J; Sterman AB; Lavan M
    Drugs R D; 2017 Mar; 17(1):103-115. PubMed ID: 27943146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tablet formulation of levothyroxine is absorbed less well than powdered levothyroxine.
    Yamamoto T
    Thyroid; 2003 Dec; 13(12):1177-81. PubMed ID: 14751040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levothyroxine liquid solution versus tablet form for replacement treatment in pregnant women.
    Cappelli C; Negro R; Pirola I; Gandossi E; Agosti B; Castellano M
    Gynecol Endocrinol; 2016; 32(4):290-2. PubMed ID: 26585420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation.
    Fallahi P; Ferrari SM; Camastra S; Politti U; Ruffilli I; Vita R; Navarra G; Benvenga S; Antonelli A
    Obes Surg; 2017 Jan; 27(1):78-82. PubMed ID: 27272506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update.
    Fallahi P; Ferrari SM; Ruffilli I; Ragusa F; Biricotti M; Materazzi G; Miccoli P; Antonelli A
    Expert Opin Drug Deliv; 2017 May; 14(5):647-655. PubMed ID: 27552635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bioequivalence of L-thyroxine tablets and a liquid L-thyroxine solution in the treatment of hypothyroid patients].
    Grussendorf M; Vaupel R; Wegscheider K
    Med Klin (Munich); 2004 Nov; 99(11):639-44. PubMed ID: 15583873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans.
    Fish LH; Schwartz HL; Cavanaugh J; Steffes MW; Bantle JP; Oppenheimer JH
    N Engl J Med; 1987 Mar; 316(13):764-70. PubMed ID: 3821822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of levothyroxine treatment on resting energy expenditure of hypothyroid dogs.
    Greco DS; Rosychuk RA; Ogilvie GK; Harpold LM; Van Liew CH
    J Vet Intern Med; 1998; 12(1):7-10. PubMed ID: 9503354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of a new pharmaceutical preparation containing L-thyroxine in solution. Preliminary report.
    Carpi A; Toscano S
    Thyroidology; 1989 Apr; 1(1):45-8. PubMed ID: 2484907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term therapy with a new liquid L-thyroxine preparation: bioequivalence with L-T4 tablets.
    Carpi A; Toni MG; Maccheroni M; De Gaudio C
    Thyroidology; 1992 Dec; 4(3):115-9. PubMed ID: 1285037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined substitution treatment with thyroxine and triiodothyronine?].
    Frey H
    Tidsskr Nor Laegeforen; 1971 Jan; 91(3):222. PubMed ID: 5539964
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of hypothyroidism in children with levothyroxine (tablets)].
    Rochiccioli P
    Ann Pediatr (Paris); 1983 Dec; 30(10):797-800. PubMed ID: 6666954
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles.
    Vaisman M; Spina LD; Eksterman LF; dos Santos MJ; Lima JS; Volpato NM; da Silva RL; de Brito AP; Noël F
    Arzneimittelforschung; 2001; 51(3):246-52. PubMed ID: 11304941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined thyroxine and triiodothyronine for thyroid replacement therapy.
    Taylor S; Kapur M; Adie R
    Br Med J; 1970 May; 2(5704):270-1. PubMed ID: 5420176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.